Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Certara, Inc. Stock Research

CERT

14.08USD-0.33(-2.29%)Market Closed
Watchlist

Market Summary

USD14.08-0.33
Market Closed
-2.29%

CERT Alerts

  • 1 major insider buys and 1 major insider sales recently.
  • Big jump in Earnings (Y/Y)

CERT Stock Price

CERT RSI Chart

CERT Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

117.33

Price/Sales (Trailing)

6.39

EV/EBITDA

43.13

Price/Free Cashflow

26.06

CERT Price/Sales (Trailing)

CERT Profitability

Operating Margin

60.90%

EBT Margin

5.08%

Return on Equity

1.28%

Return on Assets

0.89%

Free Cashflow Yield

3.84%

CERT Fundamentals

CERT Revenue

Revenue (TTM)

352.1M

Revenue Y/Y

9.29%

Revenue Q/Q

0.17%

CERT Earnings

Earnings (TTM)

19.2M

Earnings Y/Y

898.98%

Earnings Q/Q

246.54%

Price Action

52 Week Range

10.6024.96
(Low)(High)

Last 7 days

-0.1%

Last 30 days

-12%

Last 90 days

-19.6%

Trailing 12 Months

7.8%

CERT Financial Health

Current Ratio

3.71

Debt/Equity

0.27

Debt/Cashflow

0.32

CERT Investor Care

Shares Dilution (1Y)

2.11%

Diluted EPS (TTM)

0.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for CERT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-11
Pedersen Leif E
sold
-747,870
14.6
-51,224
president, chief commercal off
2023-08-22
BROSHY ERAN
bought
75,950
15.8
4,807
-
2023-08-21
BROSHY ERAN
bought
3,107
16.1
193
-
2023-08-01
SHERMAN NICOLETTE D
sold (taxes)
-20,579
19.47
-1,057
chief human resources officer
2023-06-30
Aspbury Robert
sold (taxes)
-15,679
18.19
-862
president, simcyp
2023-06-05
SMITH PATRICK F
sold
-411,691
21.55
-19,104
president, integrated drug dev
2023-05-23
BROSHY ERAN
acquired
-
-
9,360
-
2023-05-23
Crane Rosemary A
acquired
-
-
9,324
-
2023-05-17
WALSH MATTHEW M
acquired
-
-
9,067
-
2023-05-17
CASHMAN JAMES E III
acquired
-
-
9,067
-

1–10 of 50

Which funds bought or sold CERT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
10.48
-146,000
746,000
-%
2023-08-25
Yarbrough Capital, LLC
unchanged
-
-76,429
235,892
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
7.97
-599,230
2,647,950
-%
2023-08-21
BOKF, NA
sold off
-100
-313
-
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-55.39
-403,725
205,366
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
63.28
122,000
641,000
0.01%
2023-08-16
Sunbelt Securities, Inc.
added
78.28
2,114
7,921
-%
2023-08-16
Nuveen Asset Management, LLC
reduced
-6.38
-2,349,010
5,668,990
-%
2023-08-16
CASTLEARK MANAGEMENT LLC
sold off
-100
-5,174,490
-
-%
2023-08-15
Parkside Financial Bank & Trust
added
6.05
-17,207
69,253
0.02%

1–10 of 50

Latest Funds Activity

Are funds buying CERT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CERT
No. of Funds

Schedule 13G FIlings of Certara

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
6.80%
10,850,994
SC 13G/A
Feb 09, 2023
eqt avatar parent l.p.
0%
0
SC 13G/A
Jan 18, 2023
baillie gifford & co
6.40%
10,223,809
SC 13G/A
Dec 16, 2022
arsenal capital partners iii lp
2.2%
3,559,745
SC 13D
Feb 14, 2022
eqt avatar parent l.p.
23.5%
37,458,939
SC 13G/A
Feb 09, 2022
vanguard group inc
5.92%
9,310,068
SC 13G

Recent SEC filings of Certara

View All Filings
Date Filed Form Type Document
Sep 12, 2023
4
Insider Trading
Sep 11, 2023
144
Notice of Insider Sale Intent
Aug 23, 2023
4
Insider Trading
Aug 09, 2023
8-K
Current Report
Aug 09, 2023
10-Q
Quarterly Report
Aug 02, 2023
4
Insider Trading
Jul 03, 2023
4
Insider Trading

Certara News

Nasdaq
Certara Enters Oversold Territory (CERT).
Nasdaq,
2 days ago
InvestorsObserver
Marketscreener.com

Returns for CERT

Cumulative Returns on CERT

Risks for CERT

What is the probability of a big loss on CERT?

91.8%


Probability that Certara stock will be more than 20% underwater in next one year

91.8%


Probability that Certara stock will be more than 30% underwater in next one year.

57.5%


Probability that Certara stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CERT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Certara was unfortunately bought at previous high price.

Drawdowns

Financials for Certara

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue2.2%352344336324314301286275262253244239237230209
Operating Expenses-1.3%174176171170175168161202185175167112108109109
  S&GA Expenses3.4%30.0029.0027.0026.0025.0023.0020.0024.0022.0020.0019.0012.0011.0012.0011.00
  R&D Expenses0.5%30.0030.0028.0028.0026.0023.0020.0024.0023.0021.0020.0012.0012.0012.0012.00
EBITDA-100.0%-39.0038.0032.0019.0017.0016.00-41.82-34.1238.0042.0042.0047.0036.00-
EBITDA Margin-100.0%-0.11*0.11*0.10*0.06*0.06*0.05*-0.15*-0.13*0.15*0.18*0.18*0.20*0.16*-
Interest Expenses8.9%22.0020.0018.0016.0014.0016.0017.0019.0022.0022.0025.0026.0028.0027.0028.00
Earnings Before Taxes32.0%23.0017.0019.0015.003.00-1.21-3.37-63.14-58.17-50.27-50.1813.0016.007.00-9.15
EBT Margin-100.0%-0.05*0.06*0.05*0.01*0.00*-0.01*-0.23*-0.22*0.05*0.05*0.05*0.07*0.03*-
Net Income38.2%19.0014.0015.00-4.14-9.84-12.11-13.27-58.01-55.02-49.39-49.407.008.004.00-8.93
Net Income Margin-100.0%-0.04*0.04*-0.01*-0.03*-0.04*-0.05*-0.21*-0.21*0.03*0.03*0.03*0.03*0.02*-
Free Cashflow-100.0%-91.0091.0076.0072.0064.0059.0051.0047.0037.0042.0042.0032.0033.00-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets0.3%1,5721,5671,5731,5091,5021,5071,5121,4151,2651,2631,269
  Current Assets1.4%353348342305286275275505345348347
    Cash Equivalents0.4%245244237211198185187418270273273
  Net PPE-4.8%2.002.002.003.003.003.003.003.003.004.004.00
  Goodwill0.4%7227197186977017053.00181524519519
Liabilities-1.4%475482493454453459470443431435447
  Current Liabilities9.7%10394.0010377.0082.0082.0092.0070.0059.0063.0075.00
    LT Debt, Current0%3.003.003.003.003.003.003.003.003.005.005.00
    LT Debt, Non Current-0.2%289290290290291291292292293294294
Shareholder's Equity1.1%1,0971,0851,0801,0541,0481,0481,042971835827822
  Retained Earnings7.9%-54.81-59.51-60.87-70.05-73.98-73.39-75.60-65.90-64.14-61.29-62.34
  Additional Paid-In Capital0.3%1,1621,1591,1501,1441,1371,1271,1201,039897890885
Shares Outstanding0.0%160160160160156156160149147147153
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-5.6%87.0093.0093.0078.0074.0065.0060.0052.0048.0041.0045.0043.0033.0035.0038.00
Cashflow From Investing-38.8%-30.38-21.89-27.84-264-263-275-269-22.00-21.37-9.06-8.61-9.61-10.48-12.04-9.52
Cashflow From Financing-43.2%-9.58-6.69-7.36-10.04124123123359186188208-32.1434.0076.00-8.49
  Buy Backs-----------1.004.000.00-1.00

CERT Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenues$ 90,450$ 82,760$ 180,751$ 164,311
Cost of revenues36,22435,19471,08067,983
Operating expenses:    
Sales and marketing8,1117,12116,11313,232
Research and development7,8887,74117,17515,289
General and administrative14,24517,77834,01736,117
Intangible asset amortization10,58210,35521,11720,504
Depreciation and amortization expense361422772904
Total operating expenses41,18743,41789,19486,046
Income from operations13,0394,14920,47710,282
Other income (expenses):    
Interest expense(5,668)(3,879)(11,143)(7,107)
Net other income1,0102,5211,5163,362
Total other expenses(4,658)(1,358)(9,627)(3,745)
Income before income taxes8,3812,79110,8506,537
Provision for income taxes3,6753,3804,7864,916
Net income (loss)4,706(589)6,0641,621
Other comprehensive income (loss):    
Foreign currency translation adjustment1,815(7,520)4,416(10,704)
Change in fair value from interest rate swap, net of tax2,332848641912
Total other comprehensive income (loss)4,147(6,672)5,057(9,792)
Comprehensive income (loss)$ 8,853$ (7,261)$ 11,121$ (8,171)
Net income (loss) per share attributable to common stockholders:    
Basic (in dollar per share)$ 0.03$ (0.00)$ 0.04$ 0.01
Diluted (in dollar per share)$ 0.03$ 0.00$ 0.04$ 0.01
Weighted average common shares outstanding:    
Basic (in shares)158,955,822156,478,724158,568,575156,209,335
Diluted (in shares)159,906,972156,478,724159,817,688159,293,362

CERT Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 245,190$ 236,586
Accounts receivable, net of allowance for credit losses of $460 and $1,250, respectively83,95282,584
Restricted cash3,0203,102
Prepaid expenses and other current assets20,88219,980
Total current assets353,044342,252
Other assets:  
Property and equipment, net2,2062,400
Operating lease right-of-use assets12,32614,427
Goodwill721,853717,743
Intangible assets, net of accumulated amortization of $244,974 and $217,705, respectively473,805486,782
Deferred income taxes3,7033,703
Other long-term assets5,2835,615
Total assets1,572,2201,572,922
Current liabilities:  
Accounts payable3,7897,533
Accrued expenses38,65435,403
Current portion of deferred revenue52,78852,209
Current portion of long-term debt3,0203,020
Other current liabilities4,6454,993
Total current liabilities102,896103,158
Long-term liabilities:  
Deferred revenue, net of current portion2,0562,815
Deferred income taxes54,67765,046
Operating lease liabilities, net of current portion8,28510,133
Long-term debt, net of current portion and debt discount289,104289,988
Other long-term liabilities18,02822,121
Total liabilities475,046493,261
Commitments and contingencies
Stockholders' equity:  
Preferred shares, $0.01 par value, 50,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively00
Common shares, $0.01 par value, 600,000,000 shares authorized, 160,171,493 and 159,676,150 shares issued as of June 30, 2023 and December 31, 2022, respectively; 159,777,284 and 159,525,943 shares outstanding as of June 30, 2023 and December 31, 2022, respectively1,6011,596
Additional paid-in capital1,162,3171,150,168
Accumulated deficit(54,809)(60,873)
Accumulated other comprehensive loss(3,173)(8,230)
Treasury stock at cost, 394,209 and 150,207 shares at June 30, 2023 and December 31, 2022, respectively(8,762)(3,000)
Total stockholders’ equity1,097,1741,079,661
Total liabilities and stockholders’ equity$ 1,572,220$ 1,572,922
William F. Feehery
350
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.